Arcturus Therapeutics Holdings

Historical 13F Holders

Symbol
ARCT
CUSIP
03969T109
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 03969T109 since 12/18/2024, newest first.

Filer % of Class Filed
Federated Hermes, Inc. 13G/A Amendment 4
5.9% 10/7/2026
Event 9/30/2026
ARK Investment Management LLC 13G/A Amendment 10
10.4% 5/7/2026
Event 4/30/2026
Vanguard Group Inc 13G/A Amendment 3 0% 3/26/2026
Event 3/13/2026
Balyasny Asset Management L.P. 13G/A Amendment 1
0% 2/17/2026
Event 12/31/2025
ARK Investment Management LLC 13G/A Amendment 9
9.2% 2/3/2026
Event 12/31/2025
Federated Hermes, Inc. 13G/A Amendment 3
11.6% 1/8/2026
Event 12/31/2025
Balyasny Asset Management L.P. 13G
8.0% 11/14/2025
Event 9/30/2025
Amova Asset Management Americas, Inc. 13G/A Amendment 2 7.2% 11/13/2025
Event 9/30/2025
Sumitomo Mitsui Trust Group, Inc. 13G/A Amendment 2
7.2% 10/27/2025
Event 9/30/2025
ARK Investment Management LLC 13G/A Amendment 8
6.3% 7/30/2025
Event 6/30/2025
Vanguard Group Inc 13G/A Amendment 2 6.7% 7/29/2025
Event 6/30/2025
Nikko Asset Management Americas, Inc. 13G/A Amendment 1 7.1% 5/12/2025
Event 3/31/2025
Sumitomo Mitsui Trust Group, Inc. 13G/A Amendment 1
7.1% 4/25/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 5 7.8% 4/23/2025
Event 3/31/2025
State Street Corp 13G 4.9% 2/5/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 5 34.7 k $475 k
2026 Q2 141 25.0 M $168 M
2026 Q1 131 24.3 M $187 M
2025 Q4 135 23.8 M $147 M
2025 Q3 167 26.1 M $481 M
2025 Q2 162 25.9 M $338 M
2025 Q1 156 26.6 M $283 M
2024 Q4 162 26.7 M $453 M
2024 Q3 175 26.5 M $615 M
2024 Q2 186 27.4 M $664 M
2024 Q1 196 29.3 M $989 M
2023 Q4 180 26.7 M $843 M
2023 Q3 160 25.2 M $644 M
2023 Q2 151 23.6 M $678 M
2023 Q1 132 23.3 M $558 M
2022 Q4 124 24.9 M $422 M
2022 Q3 125 22.2 M $328 M
2022 Q2 144 22.2 M $354 M
2022 Q1 143 21.5 M $579 M
2021 Q4 156 20.2 M $745 M
2021 Q3 168 19.1 M $909 M
2021 Q2 148 20.5 M $694 M
2021 Q1 179 18.8 M $776 M
2020 Q4 161 20.1 M $876 M
2020 Q3 142 18.2 M $783 M
2020 Q2 127 13.0 M $607 M
2020 Q1 61 4.99 M $69.2 M
2019 Q4 56 4.64 M $51.0 M
2019 Q3 45 4.61 M $47.3 M
2019 Q2 26 1.88 M $17.7 M